Five-Month Observation of Persistent Diabetic Macular Edema after Intravitreal Injection of Ozurdex Implant
Aims. This retrospective analysis was aimed at evaluating the effectiveness of treatment of persistent diabetic macular edema with intravitreal injections of 0.7 mg dexamethasone implant Ozurdex. The study comprised three male patien...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2014/364143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aims. This retrospective analysis was aimed at evaluating the
effectiveness of treatment of persistent diabetic macular edema with
intravitreal injections of 0.7 mg dexamethasone implant Ozurdex.
The study comprised three male patients (6 eyes). Results. The
average thickness of the retina at baseline was 632 μm, the medial
BCVA was 0.8 logMAR, and corrected intraocular pressure was 13.7 mmHg.
The maximum decrease in mean retinal thickness was observed at four weeks following the
treatment and was 365 μm (−267 μm) and visual acuity
improved by an average of two lines and was 0.6 logMAR. The largest increase in mean retinal
thickness to average of 528 μm (+164 μm) occurred at 16
weeks and the average BCVA was 0.614 lines BCVA logMAR. In one eye, there was a steroid
cataract development after the third dose of dexamethasone implant of 0.7 mg. Conclusions.
The intravitreal dexamethasone implant treatment of patients with persistent diabetic
macular edema in whom laser photocoagulation proved to be ineffective and as a result
they required a monthly injection of anti-VEGF factors (Ranibizumab, Bevacizumab) may
be a good alternative to extending the interval of injections. However, reinjections involve
a high risk of developing poststeroid cataracts, which is not without significance in middle-aged patients. |
|---|---|
| ISSN: | 0962-9351 1466-1861 |